Mocetinostat (MGCD0103)

For research use only.

Catalog No.S1122 Synonyms: MG0103

68 publications

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 470 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Mocetinostat (MGCD0103) has been cited by 68 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
0.15 μM 0.29 μM 0.59 μM 1.66 μM
In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 M1HxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jOSVQ5KGh? MmDKTWM2OD1|LkC0JO69VQ>? NWDQVVl{OjZ|N{iwN|g>
BT549 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHMOFghcA>? MVTJR|UxRTRwM{ig{txO MmCxNlY{PzhyM{i=
MCF7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq3TWJvPDhiaB?= NHzWV4xKSzVyPUCuOlch|ryP M4W3[FI3Ozd6MEO4
T47D NYjuPVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrmOFghcA>? NEfuRldKSzVyPUGuNVch|ryP NET2d3gzPjN5OECzPC=>
MOLP8 NIixUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6wOFghcA>? M3u0fWlEPTB;MD62xtEhOC5yNN88US=> NYHiRVlGOjZyOUG1NVg>
Panc1 NUjRfGNFTnWwY4Tpc44hSXO|YYm= MmLqNE42NzFxMj61JO69VQ>? MUm0PEBp MU\EUXNQ NIjBPYN2eHKnZ4XsZZRmeyCvaWKtNlA{ M2HRU|I2QDd{OUSx
Panc1 M4DhR2Z2dmO2aX;uJGF{e2G7 MWWwMlUwOS9{LkWg{txO M37EeFQ5KGh? NIjQ[oFFVVOR NIH4PIlz\WS3Y3XzJIV5eHKnc4Ppc44hd2ZiWlXCNUBwdiCkb4ToJI1TVkFiYX7kJJBzd3SnaX6gcIV3\W{EoB?= MoPpNlU5PzJ7NEG=
Panc1 NXq4dFJLSXCxcITvd4l{KEG|c3H5 Mnf3NeKh|ryP MYe3NuKhcA>? MVHEUXNQ NHTH[Wx{\W6|aYTpfoV{KFCjbnOxJINmdGy|IH\vdkBo\W2laYThZolv\S2rbnT1Z4VlKGGyb4D0c5Nqew>? MlfUNlU5PzJ7NEG=
Panc1 MknzR4VtdCCYaXHibYxqfHliQYPzZZk> M4S0WVHDqM7:TR?= MWK3NuKhcA>? NGHUN2NFVVOR MonB[Y5p[W6lZYOg[4Vu[2m2YXLpcoUucW6mdXPld{Bk\WyuII\pZYJqdGm2eTDk[YNz\WG|ZR?= MlnwNlU5PzJ7NEG=
MMCs NUHFW5NITnWwY4Tpc44hSXO|YYm= MkTyNUDPxG1? NG\N[|UxNTR6IHi= MmXabY5kemWjc3XzJG5RWkFicILveIVqdiCneIDy[ZN{cW:wwrCyMlfjiJN|LkWg[o9t\A>? Mnv4NlQ1PTF|N{i=
MMCs M1jsfmZ2dmO2aX;uJGF{e2G7 M{\Fe|AvPS9zIN88US=> NVnpcnNxOjRiaB?= Mo\Ld4hwf3NiNEWt[o9t\CC|dHnteYxifGmxbjDpckBkT02SIHzleoVtew>? NEG5ZmwzPDR3MUO3PC=>
MMCs M17sVmZ2dmO2aX;uJGF{e2G7 NGTpe4oyyqEQvF2= NGSz[4ozPCCq NYXuS4VocW6lcnXhd4V{KEiDVDDhZ5Rqfmm2eR?= M4n6dlI1PDVzM{e4
MMCs NV7GUXFRTnWwY4Tpc44hSXO|YYm= MknhNeKh|ryP MkLUNlQhcA>? MV\heYdu\W62czDncI9j[WxiYXPleJlt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFMuUzlxMUSgLGg{NUt7L{G0ZYMqKGGwZDDIOE1MOTJiKFi0MWsyOmGlKR?= M2LiRVI1PDVzM{e4
MMCs NEf2fphHfW6ldHnvckBCe3OjeR?= NYfsVZlNOcLizszN M2DvN|YuOjRiaB?= M3fQS4Rwe2VvZHXw[Y5l\W62bImgbY5pcWKrdIOgeIhmKHS{aX3leIh6dGG2aX;uJIxmfmWuIH;mJGg{NUt7IDjIN{1MQW2nMzm= M1nXfFI1PDVzM{e4
BxPC-3 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;QSWM2OD1zLkGg{txO MkfjNlE{PzV4N{m=
AsPC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LyfmVEPTB;Mz65JO69VQ>? NH3jcmszOTN5NU[3PS=>
MiaPaca-2 M3v6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XENWVEPTB;MD62JO69VQ>? NWPXeXN5OjF|N{W2O|k>
Panc-1 M3vPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfxSWM2OD1zLkig{txO M4jZOlIyOzd3Nke5
PAXF 546L† NUTCUYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTFR|UxRTFwNTFOwG0> MVeyNVM4PTZ5OR?=
PAXF 1657L† NYjS[Ys4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;aSWM2OD1yLkOg{txO M3HQSlIyOzd3Nke5
HCT15 NVq0SWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr6WnlKSzVyPUCuO{DPxE1? NXPUXZNiOjF|MUe0OVU>
HT-29 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNzFOwG0> M4\yR|IyOzF5NEW1
SW48 M3zNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljoTWM2OD1yLkig{txO M1TqbVIyOzF5NEW1
SW620 NXrUeldRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PEemlEPTB;MTFOwG0> NIPsPHkzOTNzN{S1OS=>
HMEC NYHuc4dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLncotKSzVyPUG5JO69VQ>? NUL0VpM6OjF|MUe0OVU>
ANBL6  NVH3OZIzTnWwY4Tpc44hSXO|YYm= NGjmR4gyyqEQvF2= M1:2VlI1KGh? NIrvbIhmdmijbnPld{A2NUGFLXnu[JVk\WRiTVHHSU1COyCpZX7lJIV5eHKnc4Ppc44> MVGyNVE4OTh{MR?=
LP1 Mny5SpVv[3Srb36gRZN{[Xl? MYOxxsDPxE1? M37v[lI1KGh? M1rzXIVvcGGwY3XzJFUuSUNvaX7keYNm\CCPQVfFMWE{KGenbnWg[ZhxemW|c3nvci=> M{\lZVIyOTdzOEKx
HD-LM2 NH7MS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq3NuKhcA>? NX;HfoFjTE2VTx?= NHrnPI9KSzVyPUGuPFgh|ryP NFPQWmEzODh6MEGwOy=>
L428 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm3NuKhcA>? NH3OXFRFVVOR M{nrT2lEPTB;MT65OkDPxE1? MYiyNFg5ODFyNx?=
KM-H2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj6O|LDqGh? NUjVT2FGTE2VTx?= MXfJR|UxRTJwOE[g{txO M17QSlIxQDhyMUC3
HD-LM2 MYnGeY5kfGmxbjDBd5NigQ>? NWLUflh1OC5zLUKg{txO NGLyTXgzPCCqwrC= NIHGN5FFVVOR NUHBRYtRe2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=> MlXDNlA5QDBzMEe=
L428 M4f3UWZ2dmO2aX;uJGF{e2G7 MnvoNE4yNTJizszN NXK4SmJuOjRiaNMg MmC3SG1UVw>? NFLwW3p{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx NU[0OppEOjB6OECxNFc>
KM-H2 MlnJSpVv[3Srb36gRZN{[Xl? NF:1UnMxNjFvMjFOwG0> MWWyOEBpyqB? M1fuWmROW09? M1rab5Npd3e|IHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhOyCjbnSgeZBz\We3bHH0bY9vKG:oIITo[UBk\WyuIHP5Z4xmKHKnZ4XsZZRwenlicILveIVqdiCyMkG= MYeyNFg5ODFyNx?=
HD-LM2 MXPBdI9xfG:|aYOgRZN{[Xl? MUSwMlEwOC53L{Gg{txO M{fXcVQ5KGh? NFL0boZFVVOR Ml3LbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MWqyNFg5ODFyNx?=
L428 MW\BdI9xfG:|aYOgRZN{[Xl? NF7Je40xNjFxMD61M|Eh|ryP NEDWUHo1QCCq MXLEUXNQ MoKxbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MoXGNlA5QDBzMEe=
KM-H2 NYrVenVwSXCxcITvd4l{KEG|c3H5 MkPsNE4yNzBwNT:xJO69VQ>? M3\6b|Q5KGh? NXu3NpMxTE2VTx?= MXfpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MoP1NlA5QDBzMEe=
HD-LM2 NE[wS3JHfW6ldHnvckBCe3OjeR?= M2rLTFHDqM7:TR?= M17NR|I1NzR6IHi= NYjrelFxTE2VTx?= MWnkc5dvemWpdXzheIV{KFiLQWCsJIFkfGm4YYTl[EBk[XOyYYPld{A6KGGwZDCz M3PNRlIxQDhyMUC3
L428 NUXReYNKTnWwY4Tpc44hSXO|YYm= NHy2eoMyyqEQvF2= NVm4dlluOjRxNEigbC=> NHf6eFJFVVOR NEjyfG5ld3ewcnXneYxifGW|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{ NF7vOm0zODh6MEGwOy=>
KM-H2 MVXGeY5kfGmxbjDBd5NigQ>? M3\U[FHDqM7:TR?= M{H6R|I1NzR6IHi= MnfsSG1UVw>? NInFcIlld3ewcnXneYxifGW|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{ Mm[yNlA5QDBzMEe=
HD-LM2 MVTGeY5kfGmxbjDBd5NigQ>? MXqwMlUwOSEQvF2= M1PVW|I1NzR6IHi= M4K1NWROW09? Mom0eZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MlTLNlA5QDBzMEe=
L428 Ml\2SpVv[3Srb36gRZN{[Xl? NEHpbo8xNjVxMTFOwG0> NFrrcnUzPC92ODDo NVHLOWRHTE2VTx?= NXrhWYdjfXC{ZXf1cIF1\XNiVF7GMe6yKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MVGyNFg5ODFyNx?=
KM-H2 M2Xye2Z2dmO2aX;uJGF{e2G7 NUHDSlh7OC53L{Gg{txO MoniNlQwPDhiaB?= NWXXU5psTE2VTx?= NHf6Xpd2eHKnZ4XsZZRmeyCWTl[t{tEh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MlzwNlA5QDBzMEe=
HD-LM2 M2HNOWZ2dmO2aX;uJGF{e2G7 NWLQSWhLOcLizszN M4jFbFAvOjVvNEigbC=> NHHUVFFFVVOR MUDhZ5RqfmG2ZYOgUmYuc0J? MVyyNFg5ODFyNx?=
L428 MmLhSpVv[3Srb36gRZN{[Xl? NF63ZXoyyqEQvF2= Mn3VNE4zPS12ODDo NF7FPI1FVVOR NVPTSY9E[WO2aY\heIV{KE6ILXvC MVqyNFg5ODFyNx?=
KM-H2 NXSzSFdOTnWwY4Tpc44hSXO|YYm= M{DVVVHDqM7:TR?= M33aO|AvOjVvNEigbC=> NEDqW5ZFVVOR NFj4c5hi[3SrdnH0[ZMhVkZva1K= NUXPcmpIOjB6OECxNFc>
H526 NHLtXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW0TWM2OD12OECgcm0> MX[yNFY5OjZ2Mx?=
H146 M{m2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H6[WlEPTB;M{Wgcm0> NFOzfnEzODZ6Mk[0Ny=>
H82 M2jzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hzb2lEPTB;MkWwJI5O M1\LV|IxPjh{NkSz
DMS114 NXLQRnVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTUV2J[UUN3ME22OFAhdk1? NF3QcoszODZ6Mk[0Ny=>
HeLa NIPpem1HfW6ldHnvckBCe3OjeR?= MlX1NE4{NTFyIN88US=> NYridIRDQCCq M33KXGROW09? NH\udI9qdmO{ZXHz[ZMh[WOndInsZZRm\CCKMzDLPUApUDONOVHjLUBifCBzMDFOwG0> MnvhNlA2Ozh6NEC=
HeLa NX7vZlRtTnWwY4Tpc44hSXO|YYm= MXewMlMuOTBizszN NX;oSWJQQCCq Ml;4SG1UVw>? MonTbY5kemWjc3XzJINie3Cjc3WgN{BidmRiNzDhZ5RqfmG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= MW[yNFU{QDh2MB?=
HeLa MXzGeY5kfGmxbjDBd5NigQ>? M4nXSlExKM7:TdMg NGXE[o03NzF{L{K0JIg> MXfEUXNQ NXy1dmh{cW6mdXPld{BucXSxdHnjJIFk[3WvdXzheIlwdiCjbnSg[IVt[XmnZDDwNlEh\XiycnXzd4lwdg>? MXKyNFU{QDh2MB?=
HeLa  MWTGeY5kfGmxbjDBd5NigQ>? MX[xNEDPxE4EoB?= NHjYV3M4KGh? M4naTGROW09? NG\yXlllcXO{dYD0d{Bvd3KvYXygd5BqdmSuZTDjbIVkc3CxaX70JIZ2dmO2aX;u Ml\rNlA2Ozh6NEC=
PBMC  MWLBdI9xfG:|aYOgRZN{[Xl? MljqNE42NzJxMzFOwG0> MmPiNlQwPDhiaB?= M2qzfolv\HWlZYOgZZBweHSxc3nzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MV6yNFQxPjl2Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Ac-H3 / Ac-H4 / Ac-tubulin ; 

PubMed: 29186204     


Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.

Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; 

PubMed: 27551526     


(a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. 

29186204 27551526
Immunofluorescence
Nanog / MHC ; 

PubMed: 26240433     


c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.

E-cadherin / ZEB1 ; 

PubMed: 25872941     


Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.

26240433 25872941
Growth inhibition assay
Cell viability; 

PubMed: 26378038     


B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software. 

26378038
In vivo MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. [1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. [2]

Protocol

Kinase Assay:[1]
- Collapse

HDAC enzyme assay in vitro:

The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:[1]
- Collapse
  • Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells
  • Concentrations: 0-60 μM
  • Incubation Time: 72 hours
  • Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO2. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing H1437 tumors
  • Dosages: 80 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL (32.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.44
Formula

C23H20N6O

CAS No. 726169-73-9
Storage powder
in solvent
Synonyms MG0103
Smiles C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04299113 Recruiting Drug: Vinorelbine|Drug: Mocetinostat Rhabdomyosarcoma Jonsson Comprehensive Cancer Center|Mirati Therapeutics Inc.|Phase One Foundation May 14 2020 Phase 1
NCT02993991 Withdrawn Drug: Mocetinostat|Biological: Durvalumab Squamous Cell Carcinoma Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral Cavity University Health Network Toronto|Mirati Therapeutics Inc.|AstraZeneca October 10 2017 Phase 1
NCT02805660 Completed Drug: mocetinostat|Drug: durvalumab Advanced Cancer Mirati Therapeutics Inc. May 2016 Phase 1|Phase 2
NCT02236195 Completed Drug: Mocetinostat Urothelial Carcinoma Mirati Therapeutics Inc. October 2014 Phase 2
NCT00666497 Terminated Drug: Azacitidine|Drug: MGCD0103 Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS) Mirati Therapeutics Inc. June 2008 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) supplier | purchase Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) cost | Mocetinostat (MGCD0103) manufacturer | order Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID